Navigation Links
Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Date:9/8/2008

in any dose cohort after 14 days of dosing.

In a 4-week Phase 1 combination study that was conducted in 81 treatment-naive patients chronically infected with HCV genotype 1, R7128 demonstrated significant short-term antiviral activity with safety and tolerability comparable to placebo with SOC. Results from the 500mg, 1500mg and 1000mg dose cohorts (cohorts 1, 2 and 3) in 81 treatment-naive patients chronically infected with HCV genotype 1 indicated:

Preliminary results with R7128 1000mg BID with SOC indicated patients achieved a mean 5.0 log10 IU/mL decrease in HCV RNA and 88% (22 of 25) patients achieved RVR.

Results with R7128 1500mg BID with SOC indicated patients achieved a mean 5.1 log10 IU/mL decrease in HCV RNA and 85% (17 of 20) patients achieved RVR

Results with R7128 500mg BID with SOC indicated patients achieved a mean 3.8 log10 IU/mL decrease in HCV RNA and 30% (6 of 20) patients achieved RVR.

Results with placebo with SOC indicated patients achieved a mean 2.9 log10 IU/mL decrease in HCV RNA and 18.75% (3 of 16) patients achieved RVR

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with HCV. The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
2. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
3. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
4. Pharmasset Joins Russell 3000 Index
5. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
6. Pharmasset Selected to Join the NASDAQ Biotechnology Index
7. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
8. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
9. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
10. Pharmasset Receives $10 Million of Working Capital
11. Pharmasset Appoints Herbert J. Conrad as a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2014)... NY (PRWEB) July 20, 2014 ... custom quartz glass optics, and spectrophotometer calibration ... these years, NSG has released many products that ... successful product has been their solid-state calibration standards. ... liquid standards since their release in 2008. ...
(Date:7/18/2014)... 2014 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... and operating results on Tuesday, August 5, 2014, before ... a conference call and simultaneous webcast at 8:30 AM ... InformationTo access this call, dial (888) 660-6127 (U.S.) or ... be accessed from the ,Events and Presentations, page of ...
(Date:7/18/2014)... Researchers at the University of Illinois at Urbana-Champaign ... pillar-bowtie nanoantennas (pBNAs) can be used like traditional ... are much smaller than the wavelength of light ... red light). A standard optical microscope acts as ... film. , "Unlike conventional photographic film, the effect ...
(Date:7/18/2014)... Reflecting the importance of the evolution of ... Rankin, the founder and president of Customized Real ... a fresh new approach to the firm’s branding. , ... influence the success of his or her commercial clients have ... of the first in this market to fully embrace the ...
Breaking Biology Technology:How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 2How NSG Precision Cells Spectrophotometer Calibration Standards Makes NIR Work Easier 3'Nanocamera' takes pictures at distances smaller than light's own wavelength 2LEED AP Certified ITRA Global / Customized Real Estate Services Introduces New Approach to Its Branding 2
... N.J., Nov. 4 Cambrex,Corporation (NYSE: CBM ) reports third ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), -- Sales increased ... third quarter 2007. -- Adjusted EBITDA for the quarter was ... $9.7 million last year. -- Debt, net of cash was ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... pursue a pivotal (Phase II/III) randomized trial ... refractory,patients with head and neck cancers. The ... by the Company,s Board of Directors from ...
... Md., Nov. 4 PharmAthene, Inc.,(NYSE Alternext US: ... and chemical threats, announced today,that David P. Wright, ... at the Rodman and Renshaw 10th Annual Healthcare ... beginning at 2:25 p.m. E.T. in the,Holmes II ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2
(Date:7/21/2014)... Growers of annual bedding plant seedlings or plugs ... a large stem diameter and high root dry ... during shipping and transplant. To achieve these desirable ... on supplemental lighting from high-pressure sodium lamps during ... diodes (LEDs) can give greenhouse growers other lighting ...
(Date:7/21/2014)... their cells are stressed when facing temperature extremes. Worse ... in the cell are slowed down more than others, ... of whack. Yet, those cells manage to keep their ... Rochester and the European Molecular Biology Laboratory have found ... of proteins is a key process in all cells, ...
(Date:7/20/2014)... A study of 473 sets of twins followed since ... of 24-month-old identical twins had language delay compared to ... the rate of late language emergence of single-born children. ... , The results of the study were published in ... Hearing Research . , University of Kansas Distinguished ...
Breaking Biology News(10 mins):LEDs shine in bedding plant production study 2When temperatures get cold, newly-discovered process helps fruit flies cope 2Large twin study suggests that language delay due more to nature than nurture 2Large twin study suggests that language delay due more to nature than nurture 3
... things that exist underground, plant roots are out-of-sight and ... plant parts are more familiar, plant roots are equally ... crop, and dazzling ornamental lies a root system that ... for plants, extract water and nutrients from soil, and ...
... Since the terrorist attacks of 2001, the Bureau of ... water and power to millions of people, has invested ... protect its facilities and personnel, says a new report ... better communication among security staff, regional and area office ...
... WI, AUGUST 18, 2008 Serpentine soils contain highly ... farming. Successful management of serpentine soils requires accurate measurement ... in the Soil Science Society of America Journal ... accurately measure calcium content in serpentine soils. To ...
Cached Biology News:Getting to the root of the matter 2National Research Council report on security at federally managed dams 2National Research Council report on security at federally managed dams 3